Stock vs Stock Comparison

Zoetis Inc. vs AbbVie Inc.

ABBV wins the Tale of the Tape 5–4.

ZTS$77.59
ABBV$217.13

🏆 Tale of the Tape

45
ZTSABBV
28.2%Profitability (Net Margin)6.9%
12.7xValuation (P/E)106.2x
21.4%Efficiency (ROIC)8.3%
6/9Health (Piotroski F)7/9
5.4Safety (Altman Z)2.0
2.3%Growth (Rev YoY)8.6%
-0.86Risk (Sharpe 1Y)0.61
3.64xBalance Sheet (D/E)-42.50x
4.04%FCF Yield4.23%

Green = winner in each category. Higher is better except P/E (lower = cheaper).

Rolling Correlation

0.242
252-Day Correlation
0.014
126-Day Correlation

Low correlation — excellent diversification pair.

Fundamentals

MetricZTSABBV
Market Cap$32.6B$384.7B
P/E Ratio12.7x106.2x
Forward P/E10.5x13.4x
P/B9.91x-57.80x
Dividend Yield2.73%3.18%
Beta0.860.30

Quantitative Metrics

MetricZTSABBV
DCF Fair Value$130.31$126.26
DCF Upside+8.5%-38.9%
Piotroski F6/97/9
Altman Z5.432.01
Beneish M-2.44-2.87
FCF Yield4.04%4.23%
Net Debt/EBITDA1.7x3.0x
ROIC21.4%8.3%
WACC9.8%7.4%
ROIC – WACC11.6pp0.8pp
Gross Margin71.8%70.2%
Net Margin28.2%6.9%
Rev Growth YoY2.3%8.6%
Sharpe (1Y)-0.860.61
Max Drawdown 3Y-41.9%
FCF Payout Ratio39%65%

ZTS Price

Loading chart...

ABBV Price

Loading chart...

ETF Exposure

ZTS found in:

MOAT1.32%
XPH1.22%
VOT1.03%
VHT0.82%
XLV0.63%
VO0.44%
DGRW0.30%
VIG0.22%
VYM0.21%
RSP0.21%
SCHV0.19%
IWF0.15%
VONG0.13%
SPYV0.12%
SPLG0.11%
ESGV0.10%
IVV0.09%
QUS0.09%
SCHX0.09%
VTV0.09%
SCHB0.09%
ITOT0.08%
VOO0.08%
VONE0.08%
VUG0.08%
URTH0.07%
VTI0.06%
ACWI0.06%
SPY0.05%
VT0.05%
SPTM0.05%
IWD0.04%
ONEO0.03%
VONV0.03%

ABBV found in:

XLV7.07%
IYH6.86%
VHT6.04%
HDV5.61%
SCHD3.53%
DGRO2.52%
DGRW1.99%
MGV1.85%
VIG1.68%
VYM1.56%
NOBL1.49%
VTV1.46%
SDY1.42%
IWF1.39%
SCHV1.38%
VONG1.21%
XBI1.09%
ESGV0.78%
SPYV0.71%
IVV0.69%
SPLG0.68%
SCHX0.66%
SCHB0.62%
ITOT0.61%
VOO0.60%
SPY0.59%
VONE0.57%
SPTM0.55%
VTI0.54%
SPYG0.50%
URTH0.48%
ACWI0.41%
VFVA0.41%
VT0.33%
QUS0.32%
VFMV0.25%
RSP0.19%
ONEO0.03%

More Comparisons

Quant metrics computed from financial statements and 1,200+ trading days. Correlation is Pearson coefficient on daily log returns. Not investment advice.

ZTS vs ABBV: Head-to-Head Analysis

Zoetis Inc. (ZTS) and AbbVie Inc. (ABBV) represent two companies in the Healthcare sector. In our quantitative Tale of the Tape scoring, ABBV leads 5–4 across nine fundamental and risk metrics including profitability, valuation, capital efficiency, and financial health.

In terms of capital efficiency, ZTS generates a return on invested capital (ROIC) of 21.4% compared to ABBV's 8.3%. This suggests ZTS is more effective at deploying capital to generate shareholder returns.

The 252-day rolling correlation between ZTS and ABBV is 0.242, indicating low correlation, making them an effective diversification pair in a portfolio context.

ZTS appears in 34 ETFs tracked by SecuritiesDB, while ABBV appears in 38 ETFs. Investors holding broad-market ETFs may already have indirect exposure to both stocks.

Frequently Asked Questions

Which stock is the better investment, ZTS or ABBV?

Our quantitative analysis compares ZTS and ABBV across nine fundamental dimensions. ABBV wins the Tale of the Tape 5–4. However, stock selection depends on your individual risk tolerance, time horizon, and portfolio context. These metrics are computed from SEC filings and market data — they are not investment recommendations.

Are ZTS and ABBV correlated?

The 252-day correlation between ZTS and ABBV is 0.242. They have low correlation, offering good diversification.

How is the Tale of the Tape scored?

The Tale of the Tape compares both stocks across nine categories: profitability (net margin), valuation (P/E), efficiency (ROIC), health (Piotroski F-Score), safety (Altman Z-Score), growth (revenue YoY), risk (Sharpe ratio), leverage (debt-to-equity), and cash generation (FCF yield). The stock that wins more categories takes the overall score. Lower P/E and lower debt-to-equity count as wins.